Nalbuphine ER: Relief is Possible
We are developing nalbuphine ER, unlocking new market opportunities and the potential to significantly improve the quality of life of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions.
Passionate
about Progress
Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.
Passionate
about Progress
Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.
A New Hope for Patients with Chronic and Serious Neurologically Mediated Conditions
We are developing nalbuphine ER as an oral treatment for a broad range of chronic conditions for which patients have few, if any, treatment options. With its unique dual mechanism of action, nalbuphine ER has the potential to significantly improve the quality of life of patients.
Committed to Excellence in Pharmaceutical Development and Bringing Solutions to Patients
news
08/12/2019
Advancement of Nalbuphine ER Through Clinical Development in Multiple Indications NEW HAVEN, Conn. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat
06/18/2019
NEW HAVEN, Conn. , June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Company management
06/13/2019
Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clinical Trial for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) NEW HAVEN, Conn. , June 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.
